Exploiting the relevance of CA 19-9 in pancreatic cancer

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is currently the fourth most common cause of cancer-related deaths in the United States. It has a poor prognosis and remains a difficulty to treat malignancy. Over the past several decades, significant efforts have been directed towards developing new approaches to enhance the efficacy of therapeutic regimens for PDAC treatment. In recent years, the measurement of serum carbohydrate antigen 19-9 (CA 19-9) has become one of the most validated and extensively used tumour biomarkers for PDAC. In particular, serum CA 19-9 levels have been explored as a validated tool to predict either the signs of disease progression or the response to treatment. However, despite its clinical relevance, the implications on diagnosis or accurately predicting tumour resectability, and monitoring disease symptoms in PDAC patients remains limited. This current review highlights the recent updates on the applicability of CA 19-9, its exploitation, and challenges in predicting the treatment efficacy and responses in PDAC patients.

Keywords

Pancreatic ductal adenocarcinoma / tumour biomarker / carbohydrate antigen 19-9 / treatment efficacy

References

[1] Luna J,Cuatrecasas M,Núñez-Manchón E.DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth..Gut2019;68:1465-76

[2] Siegel RL,Jemal A.Cancer statistics, 2016..CA Cancer J Clin2016;66:7-30

[3] Sideras K,Kwekkeboom J,Peppelenbosch MP.Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies..Cancer Treat Rev2014;40:513-22

[4] Ischenko I,Hayman MJ.A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells..Oncotarget2015;6:15814 PMCID:PMC4599239

[5] Mielgo A.Impact of tumour associated macrophages in pancreatic cancer..BMB Rep2013;46:131 PMCID:PMC4133870

[6] Chen J,Yu J,Wang X.Meta-analysis of current chemotherapy regimens in advanced pancreatic cancer to prolong survival and reduce treatment-associated toxicities..Mol Med Rep2019;19:477-89 PMCID:PMC6297739

[7] Zhang Y,Stein S.Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity..Exp Hematol Oncol2015;4:29 PMCID:PMC4597390

[8] Lee HS,Kim SA,Jung DE.Combined use of CEMIP and CA 19-9 enhances diagnostic accuracy for pancreatic cancer..Scientific reports.2018;8:1-7 PMCID:PMC5821821

[9] Diaz CL,Hwang J,Tempero MA.CA 19-9 response: a surrogate to predict survival in patients with metastatic pancreatic adenocarcinoma..Am J Clin Oncol2019;42:898-902

[10] Yue T,Maupin KA,Andrews P.Identification of blood-protein carriers of the CA 19-9 antigen and characterization of prevalence in pancreatic diseases..Proteomics2011;11:3665-74 PMCID:PMC3517053

[11] Herrero-Zabaleta ME,Burtin P,Bara J.Monoclonal antibody against sialylated Lewis (a) antigen..Bull Cancer1987;74:387-96

[12] Jelski W,Szmitkowski M.The activity of class I, II, III, and IV of alcohol dehydrogenase isoenzymes and aldehyde dehydrogenase in pancreatic cancer..Pancreas2007;35:142-6

[13] Jelski W,Szmitkowski M.Alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) activity in the sera of patients with pancreatic cancer..Dig Dis Sci2008;53:2276-80

[14] Jelski W,Laniewska-Dunaj M.Alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) as candidates for tumor markers in patients with pancreatic cancer..J Gastrointestin Liver Dis2011;20:255-9

[15] Moniaux N,Brand RE.Multiple roles of mucins in pancreatic cancer, a lethal and challenging malignancy..Br J Cancer2004;91:1633-8 PMCID:PMC2409950

[16] Kaur S,Momi N,Batra SK.Mucins in pancreatic cancer and its microenvironment..Nat Rev Gastroenterol Hepatol2013;10:607 PMCID:PMC3934431

[17] Munkley J.The glycosylation landscape of pancreatic cancer..Oncol Lett2019;17:2569-75 PMCID:PMC6388511

[18] Bergquist JR,Shubert CR,Habermann EB.Carbohydrate antigen 19-9 elevation in anatomically resectable, early stage pancreatic cancer is independently associated with decreased overall survival and an indication for neoadjuvant therapy: a national cancer database study..J Am Coll Surg2016;223:52-65

[19] Boone BA,Zenati MS,Singhi AD.Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma..Ann Surg Oncol2014;21:4351-8

[20] Isacoff WH,Bedford R,Rahib L.Low-dose continuous 5-fluorouracil combined with leucovorin, nab-paclitaxel, oxaliplatin, and bevacizumab for patients with advanced pancreatic cancer: a retrospective analysis..Target Oncol2018;13:461-8 PMCID:PMC6096752

[21] Poruk KE,Brown K,Boucher KM.The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates..Curr Mol Med2013;13:340-51 PMCID:PMC4419808

[22] Wu Z,Wadleigh RG.CA 19-9 tumor marker: is it reliable? A case report in a patient with pancreatic cancer..Clin Adv Hematol Oncol2013;11:50-5

[23] Distler M,Kersting S.Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas-a retrospective tumor marker prognostic study..Int J Surg2013;11:1067-72

[24] Paschos KA,Bird NC.The engagement of selectins and their ligands in colorectal cancer liver metastases..J Cell Mol Med2010;14:165-74 PMCID:PMC3837616

[25] Jahan R,Smith LM,Carmicheal J.Trefoil factor(s) and CA19. 9: a promising panel for early detection of pancreatic cancer..E BioMedicine2019;42:375-85 PMCID:PMC6491718

[26] Houghton JL,Scholz WW.Preloading with unlabeled CA19. 9 targeted human monoclonal antibody leads to improved PET imaging with 89Zr-5B1..Mol pharm2017;14:908-15 PMCID:PMC5341702

[27] Wagner K,Scholz A,Menrad A.The targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer..Clin Cancer Res2008;14:4951-60

[28] Kieler M,Bianconi D,Prager GW.A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid..Ther Adv Med Oncol2019;11:1758835919853196 PMCID:PMC6640066

[29] Li X,Zhang Q,Guo CX.Modified-FOLFIRINOX in metastatic pancreatic cancer: a prospective study in Chinese population..Cancer Lett2017;406:22-6

[30] Aoki S,Murakami Y,Satoi S.Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients..BMC cancer2019;19:252 PMCID:PMC6427838

[31] Chiorean EG,Reni M,Infante JR.CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer..Ann Oncol2016;27:654-60 PMCID:PMC4803454

[32] Kim JE,Lee JK,Rhee JC.Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population..J Gastroenterol Hepatol2004;19:182-6

[33] Satake K,Homma T.CA19-9 as a screening and diagnostic tool in symptomatic patients: the Japanese experience..Pancreas1994;9:703-6

[34] Santucci N,Ortega-Deballon P,Rat P.CA 19-9 predicts resectability of pancreatic cancer even in jaundiced patients..Pancreatology2018;18:666-70

[35] Ansari D,Andersson R.Update on the management of pancreatic cancer: surgery is not enough..World J Gastroenterol2015;21:3157 PMCID:PMC4363743

[36] Chang CY,Chiu HM,Chen MF.Low efficacy of serum levels of CA 19-9 in prediction of malignant diseases in asymptomatic population in Taiwan..Hepato-gastroenterol2006;53:1-4

[37] Katz MH,Fleming JB,Lee JE.Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation..Ann Surg Oncol2010;17:1794-801 PMCID:PMC2889288

[38] Berger AC,Hoffman JP,Abrams RA.Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704..J Clin Oncol2008;26:5918 PMCID:PMC2645109

[39] Jawad ZA,Jiao LR.Highly sensitive plasmonic detection of the pancreatic cancer biomarker CA 19-9..Scientific Rep2017;7:1-7 PMCID:PMC5662715

[40] Heger U,Hinz U,Tanaka M.Induction chemotherapy in pancreatic cancer: CA 19-9 may predict resectability and survival..HPB (Oxford)2020;22:224-32

[41] Bolton NM,Brown RE,Bolton JS.Multiagent neoadjuvant chemotherapy and tumor response are associated with improved survival in pancreatic cancer..HPB2019;21:413-8

[42] van Veldhuisen E,Klompmaker S,van Laarhoven HW.Added value of CA19-9 response in predicting resectability of locally advanced pancreatic cancer following induction chemotherapy..HPB2018;20:605-11

[43] Xu HX,Wu CT,Wang WQ.Postoperative serum CA19-9, CEA and CA125 predicts the response to adjuvant chemoradiotherapy following radical resection in pancreatic adenocarcinoma..Pancreatology2018;18:671-7

[44] Choi SH,Seong J.A nomogram for predicting survival of patients with locally advanced pancreatic cancer treated with chemoradiotherapy..Radiother Oncol2018;129:340-6

[45] Bergquist JR,Shubert CR,Habermann EB.Carbohydrate antigen 19-9 elevation in anatomically resectable, early stage pancreatic cancer is independently associated with decreased overall survival and an indication for neoadjuvant therapy: a national cancer database study..J Am Coll Surg2016;223:52-65

[46] Choe JW,Kim JS,Joo MK.Usefulness of CA 19-9 for pancreatic cancer screening in patients with new-onset diabetes..Hepatobiliary Pancreat Dis Int2018;17:263-8

[47] Zheng W,Wadleigh RG.CA 19-9 tumor marker: is it reliable? a case report in a patient with pancreatic cancer..Clin Adv Hematol Oncol2013;11:50-2

[48] Ballehaninna UK.Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9..Tumor Biol2013;34:3279-92

[49] Lee IK,Gorden DL,Sung NY.Prognostic value of CEA and CA 19-9 tumor markers combined with cytology from peritoneal fluid in colorectal cancer..Ann Surg Oncol2009;16:861-70

[50] Molina V,Conill C,Escudero JM.CA 19-9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer..Tumor Biol2012;33:799-807

[51] Goh SK,Christophi C.Serum carbohydrate antigen 19-9 in pancreatic adenocarcinoma: a mini review for surgeons..ANZ J Surg2017;87:987-92

[52] Jahan R,Smith LM,Carmicheal J.Trefoil factor(s) and CA19. 9: a promising panel for early detection of pancreatic cancer..EBioMedicine2019;42:375-85 PMCID:PMC6491718